Corporate News Report: Fuan Pharmaceutical Stock Overview
Market Performance Snapshot
Fuan Pharmaceutical (ticker 300194.SZ) concluded the most recent 24‑hour trading session on Saturday, 24 November 2026, with no change in price, maintaining a flat 0 % movement through 04:09 AM Central Europe time. At the close, a single share can be acquired for approximately CNY 3.70 on the Shenzhen Stock Exchange.
- Shares Outstanding: 1.2 billion
- Market Capitalization: CNY 4.5 billion
- Turnover (last 24 h): Roughly CNY 73 million
- Year‑to‑Date Decline: -6.15 % since the end of last month
The 200‑day simple moving average sits at CNY 3.78, indicating that the current trading level is marginally below the medium‑term trend. Historically, the stock’s highest price over the past 52 weeks reached CNY 5.00 on 15 December 2025, while the low of the same period fell to CNY 3.24 on 29 June 2026. These extremes illustrate the volatility that has characterized the company’s recent performance.
Comparative Peer Activity
In the same 24‑hour window, a group of related Chinese equities also reported flat trading, offering a broader context for Fuan’s activity:
| Company | Ticker | Current Price | Market Cap (CNY bn) | P/E Ratio |
|---|---|---|---|---|
| Ahwb | 301520.SZ | 53.45 | 5.4 | 583.99 |
| Malion New Materials Lt | 300586.SZ | 7.41 | 5.4 | – |
| Chengdu Ald Aviation Manuf | 300696.SZ | 17.90 | 5.4 | 180.82 |
| Zhejiang Yunzhongma | 603130.SS | 38.98 | 5.4 | – |
| Changzhou Galaxy Century Micro‑electronics | 688689.SS | 37.00 | 5.4 | 41.42 |
The uniform lack of price movement across these stocks suggests a broader market equilibrium, with no single driver prompting a significant shift in investor sentiment during the period.
Company Profile
Fuan Pharmaceutical Group Co. Ltd., headquartered in Chongqing, China, specializes in the research, development, manufacturing, and sale of pharmaceutical intermediates, bulk drugs, and finished formulations. Its product portfolio spans anti‑infective agents, cardiovascular drugs, digestive solutions, and other therapeutic categories. The company originally operated under the name Chongqing Fuan Pharmaceutical (Group) Co. Ltd. before rebranding to its current title in August 2013. Established in 2004, Fuan has positioned itself as a key supplier within China’s expanding pharmaceutical ecosystem. Further information can be found on its official website: www.fapharm.com .
Analytical Perspective
The flat performance of Fuan Pharmaceutical, coupled with its modest trading volume relative to its market capitalization, may indicate a period of consolidation. The price hovering near the 200‑day moving average suggests that the market is awaiting clearer signals—whether from earnings releases, regulatory approvals, or macroeconomic shifts—before committing to a new direction. Investors observing the 52‑week high and low benchmarks should note the potential for volatility should the company secure a significant breakthrough in product development or secure a strategic partnership that could enhance its valuation multiples.
In the broader context, the lack of movement across peer stocks underscores a market that is currently neither bullish nor bearish, reflecting a cautious stance among market participants amid ongoing global economic uncertainties. As the week progresses, analysts will monitor any forthcoming corporate disclosures or sectoral policy changes that could tilt the balance and influence Fuan Pharmaceutical’s trajectory in the Shenzhen market.
